News

The European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.

The most recent analyses of data from the ARMOR (Antibiotic Resistance Monitoring in Ocular micRoorganisms) Surveillance Program can guide clinicians choosing antibiotic therapy for initial empiric therapy and infection prophylaxis. The information also reinforces the importance of prudent antibiotic prescribing to limit the development of bacterial resistance to existing options, according to Penny Asbell, MD.

Ophthalmology Times wants insight on antibiotics and eye infections from clinicians in the field - so the editors asked you. Readers like you helped by completing our survey and telling us about your experience with postoperative infections after eye surgery, if you use topical antibiotic prior to cataract surgery, how you choose antibiotics in a routine surgical prophylaxis, and more. The 118 U.S.-based ophthalmologists who responded were entered into a drawing to win a $200 gift card, with the winner being an ophthalmologist in Houston.

Patient excellence training should focus more on how to build a human connection while entering data into a terminal than how to use the latest and greatest diagnostic equipment. People over the age of 35 are either looking for life balance (in the case of a Millennial) or that respect he or she had in the professional arena before retirement (in the case of Baby Boomers.)

Addressing patient dissatisfaction after presbyopia-correcting IOL surgery requires listening to understand the problem. Time and patient reassurance may be adequate for resolving some issues.

The idiom “Don’t bring a knife to a gunfight” is meant to convey the importance of not entering a challenging situation without the proper equipment at hand. The concept that one must come properly prepared and equipped to any important task or confrontation is well-appreciated by ophthalmic surgeons, but this particular expression is rarely used by ophthalmologists teaching eye surgery to residents.

A 4-year study following trifocal IOL implantation (AT LISA tri 839MP, Carl Zeiss Meditec) found that the lens provided good distance, near, and intermediate visual acuity. The lens also improved patient quality of vision with better diffraction and less reduction in contrast sensitivity.

Why content is still king

One thing has remained constant since the inception of Google: the importance of unique and compelling content. So, the answer seems to be just keep adding content to your website-right? Unfortunately, no.

Cataract and refractive surgeons should use prophylaxis to avoid reactivation of the herpes simplex virus (HSV) in patients with a history of infection with this virus, according to Elizabeth Yeu, MD.

Tomasso, a vitreoretinal surgeon, recently shared a blog by someone who calls him/herself “Neuroskeptic”.Neuroskeptic penned a spoof “scientific” article about midichlorians, which are the little organisms inside cells that give Jedi Knights (the good guys in the “Star Wars” movies) their powers (and unfortunately, confer those same powers to certain bad guys, like Darth Vader).

Having explored the various options available for micro-invasive glaucoma surgery (MIGS), I now use several devices with success. One MIGS device (XEN Gel Stent, Allergan) differs from the others in that it drains aqueous into the subconjunctival space and can be performed as a stand-alone procedure without cataract surgery or combined with cataract surgery.

Assessing visual field progression in glaucoma may be more of an art than a science-and there is no one test to give reliable information that is needed about a patient, said Chris A. Johnson, PhD, DSc, FAAO, FARVO, professor, Department of Ophthalmology, and director, Visual Field Reading Center, University of Iowa, Iowa City.

Advancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.